

医学論文業績

英文原著/Original Articles (*: corresponding author)

1. Omoto E*, Deguchi S, Takaba S, Kojima K, Yano T, Katayama Y, Sunami K, Takeuchi M, Kimura F, Harada M, Kimura I. Low-dose melphalan for treatment of high-risk myelodysplastic syndromes. *Leukemia*. 1996; 10:609-614.
2. Katayama Y*, Kojima K, Yoshino T, Matsuo Y, Isokawa M, Yano T, Oka H, Yamaguchi M, Deguchi S, Tsuchiyama J, Hayashi K, Teshima T, Shinagawa K, Ishimaru F, Omoto E, Harada M. Common clonal origin of lymphocytes and plasma cells in splenic lymphoma with villous lymphocytes. *Br J Haematol*. 1997; 97:626-634.
3. Matsuo Y*, Macleod RAF, Kojima K, Kuwahara K, Sakata A, Drexler HG, Nishizaki C, Fukuda S, Inoue Y, Sezaki T, Sakaguchi N, Orita K. A novel ALL-L3 cell line, BALM-16, lacking expression of immunoglobulin chains derived from a patient with hypercalcemia. *Leukemia*. 1997; 11:2168-2174.
4. Kojima K*, Kobayashi H, Imoto S, Nakagawa T, Matsui T, Kawachi Y, Oda K, Yano T, Kobayashi H, Noguchi M, Hara M, Oshimi K. 14q11 abnormality and trisomy 8q are not common in Japanese T-cell prolymphocytic leukemia. *Int J Hematol*. 1998; 68:291-296.
5. Hara M*, Shinagawa K, Omoto E, Sunami K, Deguchi S, Narumi H, Kojima K, Azuma T, Takamatsu H, Nakao S, Harada M. Graft rejection and recovery of host-derived hematopoiesis after allogeneic bone marrow transplantation: relation to conditioning with high dose etoposide and total body irradiation. *Int J Hematol*. 1998; 68:95-100.
6. Kojima K*, Sawada T, Ikezoe T, Matsuo Y, Kobayashi H, Yano T, Sugimoto T, Imoto S, Nakagawa T, Matsui T, Yasukawa M, Hara M, Taguchi H. Defective human T-lymphotropic virus type I provirus in T-cell prolymphocytic leukaemia. *Br J Haematol*. 1999; 105:376-381.
7. Kojima K*, Yasukawa M, Miyakuni T, Harashima A, Matsuo Y, Yano T, Sezaki T, Kobayashi H, Hara M. Serum levels of parathyroid hormone related protein are not elevated in patients with T-cell prolymphocytic leukemia. *Ann Hematol*. 1999; 78:415-417.
8. Katayama Y*, Mahmut N, Takimoto H, Maeda Y, Yano T, Kojima K, Azuma T, Hara M, Imajyo K, Takahashi S, Kai T, Ohno Y, Miyamoto T, Nagafuji K, Matsue K, Takenaka K, Teshima T, Shinagawa K, Ishimaru F, Omoto E, Harada M. Hematopoietic progenitor

cells from allogeneic bone marrow transplant donors circulate in the very early post-transplant period. *Bone Marrow Transplant*. 1999; 23:659-665.

9. Maeda Y*, Teshima T, Yamada M, Shinagawa K, Nakao S, Ohno Y, Kojima K, Hara M, Nagafuji K, Hayashi S, Fukuda S, Sawada H, Matsue K, Takenaka K, Ishimaru F, Ikeda K, Niiya K, Harada M. Monitoring of human herpesviruses after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation. *Br J Haematol*. 1999; 105:295-302.
10. Nakayama H, Ishimaru F*, Avitahl N, Sezaki N, Fujii N, Nakase K, Ninomiya Y, Harashima A, Minowada J, Tsuchiyama J, Imajoh K, Tsubota T, Fukuda S, Sezaki T, Kojima K, Hara M, Takimoto H, Yorimitsu S, Takahashi I, Miyata A, Taniguchi S, Tokunaga Y, Gondo H, Niho Y, Nakao S, Kyo T, Dohy H, Kamada N, Harada M. Decreases in Ikaros activity correlate with blast crisis in patients with chronic myelogenous leukemia. *Cancer Res*. 1999; 59:3931-3934.
11. Yasukawa M*, Ohminami H, Kojima K, Inokuchi K, Nishimura Y, Fujita S. Analysis of HLA-DRB1 alleles in Japanese patients with chronic myelogenous leukemia. *Am J Hematol*. 2000; 63:99-101.
12. Yasukawa M*, Ohminami H, Kojima K, Hato T, Hasegawa A, Takahashi T, Hirai H, Fujita S. HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia derived dendritic cells to CD4(+) T lymphocytes. *Blood*. 2001; 98:1498-1505.
13. Kojima K*, Kaneda K, Yasukawa M, Tanaka K, Inoue T, Yamashita T, Dansako H, Sakugawa TS, Kozuka T, Hara M, Tanimoto M. Specificity of polymerase chain reaction-based clonality analysis of immunoglobulin heavy chain gene rearrangement for the detection of bone marrow infiltrate in B-cell lymphoma-associated haemophagocytic syndrome. *Br J Haematol*. 2002; 119:616-621.
14. Kaneda K, Kojima K*, Takeuchi M, Takimoto H, Takaba S, Shinagawa K, Kobayashi H, Miyata A, Hara M, Tanimoto M. Can t(8;21) oligoblastic leukemia be called myelodysplastic syndromes? *Eur J Haematol*. 2002; 69:165-170.
15. Fujii K, Aoyama M, Shinagawa K, Matsuo K*, Takenaka T, Ikeda K, Kojima K, Ishimaru I, Kiura K, Ueoka H, Niiya K, Tanimoto M, Harada M. Risk of Neutropenic Fever and Early Infectious Complications after Autologous Peripheral Blood Stem Cell Transplantation for Malignant Diseases. *Int J Hematol*. 2002; 76:186-191.

16. Kozuka T*, Ikeda K, Teshima T, Kojima K, Matsuo K, Bessho A, Sunami K, Hiramatsu Y, Maeda Y, Noguchi T, Yamamoto K, Fujii N, Imai T, Takenaka K, Shinagawa K, Ishimaru F, Niiya K, Koide N, Tanimoto M, Harada M. Predictive value of circulating immature cell counts in peripheral blood for timing of peripheral blood progenitor cell collection after G-CSF plus chemotherapy-induced mobilization. *Transfusion*. 2002; 42:1514-1522.
17. Makita M, Azuma T, Hamaguchi H, Niiya H, Kojima K, Fujita S, Tanimoto M, Harada M, Yasukawa M*. Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4(+) T lymphocytes. *Leukemia*. 2002; 16:2400-2407.
18. Matsuo Y*, Drexler HG, Kojima K, Sugimoto A, Harashima A, Okochi A, Hara M, Orita K. Novel B-cell acute lymphoblastic leukemia sister cell lines BALM 19-23 and BALM-26 with interclonal proliferative and phenotypic heterogeneity from a patient with hypercalcemia. *Hum Cell*. 2002; 15:160-170.
19. Matsuo Y*, Drexler HG, Kaneda K, Kojima K, Ohtsuki Y, Hara M, Yasukawa M, Tanimoto M, Orita K. Megakaryoblastic Leukemia cell line MOLM-16 derived from minimally differentiated acute leukemia with Myeloid/NK precursor phenotype. *Leuk Res*. 2003; 27:165-171.
20. Kojima K*, Kaneda K, Yoshida C, Dansako H, Fujii N, Yano T, Shinagawa K, Yasukawa M, Fujita S, Tanimoto M. A novel fusion variant of the MORF and CBP genes detected in therapy-related myelodysplastic syndrome with t(10;16)(q22;p13). *Br J Haematol* 2003; 120:271-273.
21. Yanai F, Ishii E, Kojima K, Hasegawa A, Azuma T, Hirose S, Suga N, Mitsudome A, Zaito M, Ishida Y, Shirakata Y, Sayama K, Hashimoto K, Yasukawa M*. Essential Roles of Perforin in Antigen-Specific Cytotoxicity Mediated by Human CD4(+) T Lymphocytes: Analysis Using the Combination of Hereditary Perforin-Deficient Effector Cells and Fas Deficient Target Cells. *J Immunol*. 2003; 170:2205-2213.
22. Matsuo Y*, Drexler HG, Harashima A, Okochi A, Hasegawa A, Kojima K, Orita K. Induction of CD28 on the new myeloma cell line MOLP-8 with t(11;14)(q13;q32) expressing δ/λ type immunoglobulin. *Leuk Res*. 2004; 28:869-877.
23. Kojima K*, Sakai I, Hasegawa A, Niiya H, Azuma T, Matsuo Y, Fujii N, Tanimoto M, Fujita S. FLJ10849, a septin family gene, fuses MLL in a novel leukemia cell line CNLBC1 derived from chronic neutrophilic leukemia in transformation with t(4;11)(q21;q23). *Leukemia*. 2004; 18:998-1005.

24. Kozuka T*, Ikeda K, Teshima T, Yoshida C, Shinagawa K, Kojima K, Matsuo K, Bessho A, Sunami K, Hiramatsu Y, Maeda Y, Noguchi T, Yamamoto K, Fujii N, Imai T, Kusumoto KK, Masuda K, Takenaka K, Ishimaru F, Niiya K, Koide N, Tanimoto M, Harada M. Peripheral blood circulating immature cell counts predict CD34+ cell yields in G-CSF-induced PBPC mobilization in healthy donors. *Transfusion*. 2004; 44:526-532.
25. Takeuchi K, Sakai I*, Narumi H, Yasukawa M, Kojima K, Minamoto Y, Fujisaki T, Tanimoto K, Hara M, Numata A, Gondo H, Takahashi M, Fujii N, Masuda K, Fujita S. Expression of SOCS3 mRNA in bone marrow cells from CML patients associated with cytogenetic response to IFN-alpha. *Leuk Res*. 2005; 29:173-178.
26. Matsuo Y*, Drexler HG, Harashima A, Okochi A, Kojima K, Asakura S, Tanimoto M, Orita K. Acute myeloid leukemia cell lines MOLM-17 and MOLM-18 derived from patient with advanced myelodysplastic syndromes. *Leuk Res*. 2005; 29:701-710.
27. Kojima K*, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T, Ruvolo V, Tsao T, Zeng Z, Vassilev LT, *Andreeff M. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. *Blood*. 2005; 106:3150-3159.
28. Kojima K, Konopleva M, McQueen T, O'brien S, Plunkett W, Andreeff M*. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. *Blood*. 2006; 108:993-1000.
29. Kojima K, Konopleva M, Samudio IJ, Schober WD, Bornmann WG, Andreeff M*. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML. *Cell Cycle*. 2006; 5:2778-2786.
30. Kojima K, Konopleva M, Samudio IJ, Ruvolo V, Andreeff M*. Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in AML cells. *Cancer Res*. 2007; 67:3210-3219.
31. Kojima K *, Shimanuki M, Shikami M, Samudio IJ, Ruvolo V, Corn P, Hanaoka N, Konopleva M, Andreeff M, Nakakuma H. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. *Leukemia*. 2008; 22:1728-1736.
32. Kojima K, Konopleva M, Tsao T, Nakakuma H, Andreeff M*. Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along

- with reduced endoreduplication in acute myelogenous leukemia. *Blood*. 2008; 112:2886-2895.
33. Kojima K *, Shimanuki M, Shikami M, Andreeff M, Nakakuma H. Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML. *Cancer Sci*. 2009; 100:1128-1136.
34. Hanaoka N, Nakakuma H*, Horikawa K, Nagakura S, Tsuzuki Y, Shimanuki M, Kojima K, Yonemura Y, Kawaguchi T. NKG2D-mediated immunity underlying paroxysmal nocturnal haemoglobinuria and related bone marrow failure syndromes. *Br J Haematol*. 2009; 146:538-545.
35. Kojima K *, Konopleva M, Tsao T, Andreeff M, Ishida H, Shiotsu Y, Jin L, Tabe Y, Nakakuma H. Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 via Mcl-1/Noxa axis. *Leukemia*. 2010; 24:33-43.
36. Kojima K *, Burks JK, Arts J, Andreeff M. The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias. *Mol Cancer Ther*. 2010; 9:2545-2557.
37. Jin L, Tabe Y*, Kojima K, Zhou Y, Pittaluga S, Konopleva M, Miida T, Raffeld M. MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma. *Cancer Letters*. 2010; 299:161-170.
38. Kojima K, McQueen T, Chen Y, Jacamo R, Konopleva M, Shinojima N, Shpall E, Huang X, Andreeff M*. p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1 α -mediated down-regulation of CXCL12. *Blood*. 2011; 118:4431-4439.
39. Kojima K, Duvvuri S, Ruvolo V, Samaniego F, Younes A, Andreeff M*. Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737. *Cancer*. 2012; 118:1023-1031.
40. Sugihara E, Shimizu T, Kojima K, Onishi N, Kai K, Ishizawa J, Nagata K, Hashimoto N, Honda H, Kanno M, Miwa M, Okada S, Andreeff M, Saya H*. Ink4a and Arf are crucial factors in the determination of the cell of origin and the therapeutic sensitivity of Myc-induced mouse lymphoid tumor. *Oncogene*. 2012; 31:2849-2861.
41. Tsao T, Shi Y, Kornblau S, Lu H, Konoplev S, Antony A, Ruvolo V, Qiu YH, Zhang N, Coombes KR, Andreeff M, Kojima K †, Konopleva M †* († co-senior authors).

Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. *Ann Hematol.* 2012; 91:1861-1870.

42. Kojima K*, Kornblau SM, Ruvolo V, Dilip A, Duvvuri S, Davis RE, Zhang M, Wang Z, Coombes KR, Zhang N, Qiu YH, Burks JK, Kantarjian H, Shacham S, Kauffman M, Andreeff M. Prognostic impact and targeting of CRMI in acute myeloid leukemia. *Blood.* 2013; 121:4166-4174.
43. Jin L, Tabe Y, Kojima K, Shikami M, Benito J, Ruvolo V, Wang RY, McQueen T, Ciurea SO, Miida T, Andreeff M, Konopleva M*. PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment. *J Mol Med (Berl).* 2013; 91:1383-1397.
44. Lu H †, Kojima K †, Battula VL, Korchin B, Shi Y, Chen Y, Spong S, Thomas DA, Kantarjian H, Lock RB, Andreeff M, Konopleva M* († equal contribution). Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia pre-clinical models: anti-CTGF monoclonal antibody attenuates leukemia growth. *Ann Hematol.* 2014; 98:485-492.
45. Yoshimura M, Ishizawa J, Ruvolo V, Dilip A, Quintas-Cardama A, McDonnell TJ, Neelapu SS, Kwak LW, Shacham S, Kauffman M, Tabe Y, Yokoo M, Kimura S, Andreeff M, Kojima K*. Induction of p53-mediated transcription and apoptosis by Exportin-1 (XPO1) inhibition in mantle cell lymphoma. *Cancer Sci.* 2014; 105:795-801.
46. Tabe Y †, Kojima K †, Yamamoto S, Sekihara K, Matsushita H, Davis RE, Wang Z, Ma W, Ishizawa J, Kazuno S, Kauffman M, Shacham S, Fujimura T, Ueno T, Miida T, Andreeff M* († equal contribution). Ribosomal biogenesis and translational flux inhibition by the selective inhibitor of nuclear export (SINE) XPO1 antagonist KPT-185. *PLoS One.* 2015; 10:e0137210.
47. Ishizawa J, Kojima K, McQueen T, Ruvolo V, Chachad D, Noguerras-Gonzalez GM, Huang X, Pierceall WE, Dettman EJ, Cardone MH, Shacham S, Konopleva M, Andreeff M*. Mitochondrial profiling of acute myeloid leukemia in the assessment of response to apoptosis modulating drugs. *PLoS One.* 2015; 10:e0138377.
48. Borthakur G, Duvvuri S, Ruvolo V, Tripathi DN, Piya S, Burks J, Jacamo R, Kojima K, Ruvolo P, Fueyo-Margareto J, Konopleva M, Andreeff M*. MDM2 Inhibitor, Nutlin 3a, induces p53 dependent autophagy in acute leukemia by AMP kinase activation. *PLoS One.* 2015; 10:e0139254.

49. Harada M, Benito J, Yamamoto S, Kaur S, Arslan D, Ramirez S, Jacamo R, Platanias L, Matsushita H, Fujimura T, Kazuno S, Kojima K, Tabe Y, Konopleva M*. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression. *Oncotarget*. 2015; 6:37930-37947.
50. Nishida Y, Maeda A, Chachad D, Ishizawa J, Yi Hua Q, Kornblau SM, Kimura S, Andreeff M, Kojima K*. Preclinical activity of the novel BMI-1 inhibitor PTC-209 in acute myeloid leukemia: implications for leukemia therapy. *Cancer Sci*. 2015; 106:1705-1713.
51. Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Chonghaile TN, Gonzalo O, Qiu Y, Jeremias I, Debose L, O'Brien E, Ma H, Zhou P, Jacamo R, Park E, Coombes KR, Zhang N, Thomas DA, O'Brien S, Kantarjian HM, Levenson JD, Kornblau SM, Andreeff M, Müschen M, Zweidler-McKay PA, Mulloy JC, Letai A, Milne TA*, Konopleva M*. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. *Cell Rep*. 2015; 13:2715-2727.
52. Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen JE, Wang Z, Ma W, Lee HC, Orłowski R, Sarbassov dos D, Lorenzi PL, Huang X, Neelapu SS, McDonnell T, Miranda RN, Wang M, Kantarjian H, Konopleva M, Davis RE*, Andreeff M*. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. *Sci Signal*. 2016; 9:ra17.
53. Andreeff M*, Kelly KR, Yee K, Assouline S, Strair R, Popplewell L, Bowen D, Martinelli G, Drummond MW, Vyas P, Kirschbaum M, Iyer SP, Ruvolo V, González GM, Huang X, Chen G, Graves B, Blotner S, Bridge P, Jukofsky L, Middleton S, Reckner M, Rueger R, Zhi J, Nichols G, Kojima K. Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. *Clin Cancer Res*. 2016; 22:868-876.
54. Kojima K*, Maeda A, Yoshimura M, Nishida Y, Kimura S. The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma. *Oncotarget*. 2016; 7:69625-69637.
55. Nishida Y, Maeda A, Kim MJ, Cao J, Kubota Y, Ishizawa Y, Al Rawi AN, Kato Y, Iwama A, Fujisawa M, Matsue K, Weetall M, Dumble M, Andreeff M, Davis TW, Branstrom A, Kimura S, Kojima K*. The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells. *Blood Cancer J*. 2017; 7:e527.

56. Ishizawa J, Sugihara E, Kuninaka S, Mogushi K, Kojima K, Benton CB, Zhao R, Chachad D, Hashimoto N, Jacamo RO, Qiu Y, Yoo SY, Okamoto S, Andreeff M, Kornblau SM, Saya H*. FZR1 loss increases sensitivity to DNA damage and consequently promotes murine and human B cell acute leukemia. *Blood*. 2017; 129:1958-1968.
57. Itamura H, Kubota Y*, Shindo T, Ando T, Kojima K, Kimura S. Elderly Patients With Chronic Myeloid Leukemia Benefit From a Dasatinib Dose as Low as 20 mg. *Clin Lymphoma Myeloma Leuk*. 2017; 17:370-374.
58. Nishida Y, Kimura S*, Mizobe H, Yamamichi J, Kojima K, Kawaguchi A, Fujisawa M, Matsue K. Automatic digital quantification of bone marrow myeloma volume in appendicular skeletons - clinical implications and prognostic significance. *Sci Rep*. 2017; 7:12885.
59. Maeda A, Nishida Y, Weetall M, Cao L, Branstrom A, Ishizawa J, Nii T, Schober WD, Abe Y, Matsue K, Yoshimura M, Kimura S, Kojima K*. Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma. *Oncotarget*. 2018; 9:28547-28560.
60. Ishizawa J, Nakamaru K, Seki T, Tazaki K, Kojima K, Chachad D, Zhao R, Heese L, Ma W, Ma MCJ, DiNardo C, Pierce S, Patel KP, Tse A, Davis RE, Rao A, Andreeff M*. Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. *Cancer Res*. 2018; 78:2721-2731.
61. Ureshino H*, Kusaba K, Kidoguchi K, Sano H, Nishioka A, Itamura H, Yoshimura M, Yokoo M, Shindo T, Kubota Y, Ando T, Kojima K, Sueoka E, Kimura S. Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma. *Ann Hematol*. 2019; 98:465-471.
62. Fujisawa S, Ueda Y, Usuki K, Kobayashi H, Kondo E, Doki N, Nakao T, Kanda Y, Kosugi N, Kosugi H, Kumagai T, Harada H, Shikami M, Maeda Y, Sakura T, Inokuchi K, Saito A, Nawa Y, Ogasawara M, Nishida J, Kondo T, Yoshida C, Kuroda H, Tabe Y, Maeda Y, Imajo K, Kojima K, Morita S, Komukai S, Kawaguchi A, Sakamoto J, Kimura S*. Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial). *Int J Clin Oncol*. 2019; 24:445-453.
63. Ishizawa J, Zarabi SF, Davis RE, Halgas O, Nii T, Jitkova Y, Zhao R, St-Germain J, Heese LE, Egan G, Ruvolo VR, Barghout SH, Nishida Y, Hurren R, Ma W, Gronda M, Link T, Wong K, Mabanglo M, Kojima K, Borthakur G, MacLean N, Ma MCJ, Leber AB, Minden

MD, Houry W, Kantarjian H, Stogniew M, Raught B, Pai EF, Schimmer AD, Andreeff M*. Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality. *Cancer Cell*. 2019; 35:721-737.

64. Nii T, Prabhu VV, Ruvolo V, Madhukar N, Zhao R, Mu H, Heese L, Nishida Y, Kojima K, Garnett MJ, McDermott U, Benes CH, Charter N, Deacon S, Elemento O, Allen JE, Oster W, Stogniew M, Ishizawa J*, Andreeff M. Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia. *Leukemia*. 2019;33:2805-2816.
65. Okamoto S, Ureshino H*, Kidoguchi K, Kusaba K, Kizuka-Sano H, Sano H, Nishioka A, Yamaguchi K, Kamachi K, Itamura H, Yoshimura M, Yokoo M, Shindo T, Kubota Y, Ando T, Kojima K, Kawaguchi A, Sueoka E, Kimura S. Clinical impact of the CONUT score in patients with multiple myeloma. *Ann Hematol*. 2020;99:113-119.
66. Watanabe T, Yamashita S, Ureshino H, Kamachi K, Kurahashi Y, Fukuda-Kurahashi Y, Yoshida N, Hattori N, Nakamura H, Sato A, Kawaguchi A, Sueoka-Aragane N, Kojima K, Okada S, Ushijima T, Kimura S, Sueoka E*. Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis using the new oral demethylating agent OR-2100. *Blood*. 2020; 36:871-884.
67. Yamauchi N, Maruyama D, Choi I, Atsuta Y, Sakai R, Miyashita K, Moriuchi Y, Tsujimura H, Kubota N, Yamamoto G, Igarashi T, Izutsu K, Yoshida S, Kojima K, Uchida T, Inoue Y, Tsukamoto N, Ohtsuka E, Suzuki S, Inaguma Y, Ichikawa S, Gomyo H, Ushijima Y, Nosaka K, Kurata M, Tanaka Y, Ueda R, Mizokami M, Kusumoto S*. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy. *Cancer Sci*. 2021;112:1943-1954.
68. Nishida Y, Zhao R, Heese LE, Akiyama H, Patel S, Jaeger AM, Jacamo RO, Kojima K, Ma MCJ, Ruvolo VR, Chachad D, Devine W, Lindquist S, Davis RE, Porco JA Jr, Whitesell L, Andreeff M*, Ishizawa J*. Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML. *Leukemia* 2021;35:2469-2481.
69. Nishimori T, Higuchi T, Hashida Y, Ujihara T, Taniguchi A, Ogasawara F, Kitamura N, Murakami I, Kojima K, Daibata M*. Development of a novel cell line-derived xenograft model of primary herpesvirus 8-unrelated effusion large B-cell lymphoma and antitumor activity of birabresib in vitro and in vivo. *Cancer Med*. 2021;10:8976-8987.

70. Ogasawara F, Higuchi T, Nishimori T, Hashida Y, Kojima K, Daibata M*. Targeting VEGF with bevacizumab inhibits malignant effusion formation of primary human herpesvirus 8-unrelated effusion large B-cell lymphoma in vivo. *J Cell Mol Med.* 2022;26:5580-5589.
71. Ogasawara F, Yoshida S, Yamane M, Takamatsu K, Arakawa Y, Nishida Y, Komatsu M, Yokoyama A, Yamagishi Y, Kojima K*. COVID-19 Cluster in the Hematology/Respirology Ward of a University Hospital during the Seventh Wave of the SARS-CoV-2 Pandemic in Japan: A Descriptive Study. *Intern Med.* 2023;62:1265-1271.
72. Hosono N, Chi S, Yamauchi T, Fukushima K, Shibayama H, Katagiri S, Gotoh A, Eguchi M, Morishita T, Ogasawara R, Kondo T, Yanada M, Yamamoto K, Kobayashi T, Kuroda J, Usuki K, Utsu Y, Yoshimitsu M, Ishitsuka K, Ono T, Takahashi N, Iyama S, Kojima K, Nakamura Y, Fukuhara S, Izutsu K, Abutani H, Yamauchi N, Yuda J, Minami Y*; All HM-SCREEN-Japan 01 investigators. Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01. *Cancer Sci.* 2023 114:2098-2108.
73. Kurayoshi K, Takase Y, Ueno M, Ohta K, Fuse K, Ikeda S, Watanabe T, Nishida Y, Horike SI, Hosomichi K, Ishikawa Y, Tadokoro Y, Kobayashi M, Kasahara A, Jing Y, Shoulkamy MI, Meguro-Horike M, Kojima K, Kiyoi H, Sugiyama H, Nagase H, Tajima A, Hirao A*. Targeting cis-regulatory elements of FOXO family is a novel therapeutic strategy for induction of leukemia cell differentiation. *Cell Death Dis.* 2023;14:642.
74. Usuki K*, Ohtake S, Honda S, Matsuda M, Wakita A, Nawa Y, Takase K, Maeda A, Sezaki N, Yokoyama H, Takada S, Hirano D, Tomikawa T, Sumi M, Yano S, Handa H, Ota S, Fujita H, Fujimaki K, Mugitani A, Kojima K, Kajiguchi T, Fujimoto K, Asou N, Usui N, Ishikawa Y, Katsumi A, Matsumura I, Kiyoi H, Miyazaki Y. Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11). *Int J Hematol.* 2024;119:24-38.
75. Nishida Y, Ishizawa J, Ayoub E, Montoya RH, Ostermann LB, Muftuoglu M, Ruvolo VR, Patsilevas T, Scruggs DA, Khazaei S, Mak PY, Tao W, Carter BZ, Boettcher S, Ebert BL, Daver NG, Konopleva M, Seki T, Kojima K, Andreeff M*. Enhanced *TP53* reactivation disrupts *MYC* transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias. *Sci Adv.* 2023;9(48):eadh1436.
76. Usuki K*, Ohtake S, Honda S, Matsuda M, Wakita A, Nawa Y, Takase K, Maeda A, Sezaki N, Yokoyama H, Takada S, Hirano D, Tomikawa T, Sumi M, Yano S, Handa H, Ota S, Fujita H, Fujimaki K, Mugitani A, Kojima K, Kajiguchi T, Fujimoto K, Asou N, Usui N, Ishikawa Y, Katsumi A, Matsumura I, Miyazaki Y, Kiyoi H. Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11). *Int J Hematol.* 2024;119:130-145.

77. Egawa Y, Higuchi T, Hashida Y, Ueno K, Kojima K, Daibata M*. Novel paired CD13-negative (MT-50.1) and CD13-positive (MT-50.4) HTLV-1-infected T-cell lines with differential regulatory T cell-like activity. *Sci Rep*. 2024;14:12549.
78. Muta T, Masamoto Y, Yamamoto G, Kurahashi S, Kameoka Y, Ota S, Matsuki E, Ozeki K, Toyama T, Takahashi N, Kumode T, Aotsuka N, Yoshimura T, Tamura H, Omi A, Shibayama K, Watanabe A, Isobe Y, Kojima K, Takizawa J, Nagai H, Suzumiya J, Aoki S. Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit study. *Int J Hematol*. 2024 Nov 26. doi: 10.1007/s12185-024-03875-0. Epub ahead of print. PMID: 39586984.

英文症例報告/Case Reports (*: corresponding author)

1. Kojima K*, Omoto E, Katayama Y, Uno M, Takada I, Kimura G, Kanehiro A, Tada S, Hayashi K, Kimura I, Sanada H, Harada M. Autoimmune Hemolytic Anemia in Allergic Granulomatous Angitis (Churg-Strauss Syndrome). *Int J Hematol*. 1996; 63:149-154.
2. Kojima K*, Sasaki T. Venous Occlusive Disease in Hypereosinophilic Syndrome. *Intern Med*. 1995; 34:1194-1197.
3. Katayama Y*, Kojima K, Omoto E, Harada M. Androgen therapy in combination with granulocyte colony-stimulating factor and erythropoietin in a patient with refractory anemia. *Int J Hematol*. 1996; 65: 89-92.
4. Kojima K*, Miyake M, Nakagawa H, Yunoki Y, Ogurusu K, Saino S, Wani T, Kawaguchi Y. Multiple Gastric Carcinoids and Pituitary Adenoma in Type A gastritis. *Intern Med*. 1997; 36:787-789.
5. Kojima K*, Taniwaki M, Yoshino T, Katayama Y, Sunami K, Fukuda S, Omoto E, Harada M, Sezaki T. Trisomy 12 and t(14;18) in B-cell chronic lymphocytic leukemia. *Int J Hematol*. 1998; 67:199-203.
6. Kojima K*, Sawada T, Yasukawa M, Matsuo Y, Yakushijin Y, Narumi H, Azuma T, Takimoto H, Hara M. Deleted HTLV provirus in peripheral blood cells of a patient with T-cell prolymphocytic leukaemia. *Br J Haematol*. 1998; 100:567-570.
7. Kojima K*, Omoto E, Hara M, Sasaki K, Katayama Y, Nawa Y, Kimura Y, Azuma T, Takimoto H, Harada M. Myelodysplastic syndrome with translocation (8;21): a distinct myelodysplastic syndrome entity or M2-acute myeloid leukemia with extensive myeloid maturation? *Ann Hematol*. 1998; 76:279-282.

8. Kojima K*, Inoue Y, Katayama Y, Kataoka M, Sunami K, Fukuda S, Sezaki T, Omoto E, Harada M. Improvement with disodium cromoglycate of neutrophil phagocytosis and respiratory burst activity in a patient with hyperimmunoglobulin E syndrome. *Allergy*. 1998; 53:1101-1103.
9. Kojima K*, Yasukawa M, Hara M, Nawa Y, Kimura Y, Narumi H, Fujita S. Familial occurrence of chronic neutrophilic leukaemia. *Br J Haematol*. 1999; 105:428-430.
10. Kojima K*, Yasukawa M, Ishimaru F, Dansako H, Matsuo Y, Kimura Y, Nawa Y, Hara M, Harada M. Additional translocation (8;21)(q22;q22) in a patient with Philadelphia-positive chronic myelogenous leukaemia in the blastic phase. *Br J Haematol*. 1999; 106:720-722.
11. Kojima K*, Mannami T, Yoshino T, Kawasaki H, Sasaki K, Maeda T, Furuya K, Harada M, Hara M. Histologic transformation of follicular lymphoma after allogeneic bone marrow transplantation. *Bone Marrow Transplant*. 2000; 26:581-583.
12. Miyata A*, Kojima K, Yoshino T, Fujii S, Shinagawa K, Ichimura K. Concurrent Hodgkin's disease (mixed cellularity type) and T-cell chronic lymphocytic leukemia/prolymphocytic leukemia. *Int J Hematol*. 2001; 73:230-235.
13. Fujiwara T*, Kojima K, Ishimaru F, Harada M. Huge skin tumor diffuse large cell lymphoma associated with essential thrombocytosis. *Intern Med*. 2001; 40:843.
14. Sugimoto T, Imoto S*, Matsuo Y, Kojima K, Yasukawa M, Murayama T, Kohfuku J, Mizuno I, Yakushijin K, Sada A, Nishimura R, Koizumi T. T cell receptor $\gamma \delta$ T-cell leukemia with the morphology of T-cell prolymphocytic leukemia and a postthymic immunophenotype. *Ann Hematol*. 2001; 80:749-751.
15. Sakugawa M, Kojima K*, Kaneda K, Masuda K, Dansako H, Shinagawa K, Ishimaru F, Ikeda K, Niiya K, Harada M, Tanimoto M. Therapy related myelodysplastic syndrome/acute myeloid leukemia M2 and translocation (8;21). *Ann Hematol*. 2001; 80:763-766.
16. Ito W, Kojima K*, Fujiwara K, Nanba Y, Yoshino T, Shinagawa K, Ishimaru F, Ikeda K, Niiya K, Tanimoto M. Thymic Epithelial Hyperplasia with Nodular Sclerosis Hodgkin's Disease. *Leuk Lymphoma*. 2002; 43:2229-2231.

17. Kojima K*, Fujii N, Takata S, Tezen T, Morikawa T, Kaneda K, Takenaka K, Itoshima I, Tanimoto M. Bilateral adrenal hemorrhage in essential thrombocythemia. *Ann Hematol.* 2002; 81:350-351.
18. Kojima K, Kurokawa SM*, Tanimoto K, Kojima Y, Hara M, Yoshino T, Harada M, Tanimoto M, Nishioka K, Kato T. Clonal expansion of limited T cell clonotypes in affected muscle from a patient with post-transplant polymyositis. *Bone Marrow Transplant.* 2002; 30:467-470.
19. Yoshida C, Kojima K*, Shinagawa K, Hashimoto D, Asakura S, Takata S, Tanimoto M. Fournier's gangrene after unrelated cord blood stem cell transplantation. *Ann Hematol.* 2002; 81:538-539.
20. Emori Y, Sakugawa M, Niiya K*, Kiguchi T, Kojima K, Takenaka K, Shinagawa K, Ishimaru F, Ikeda K, Tanimoto M, Yamasaki R, Ohara N, Harada M. Life-threatening bleeding and acquired factor V deficiency associated with primary systemic amyloidosis. *Blood Coagul Fibrinolysis.* 2002; 13:555-559.
21. Fujii N*, Ikeda K, Takahashi N, Kojima K, Kobayashi Y, Ashiba A, Takenaka K, Fukuda S, Shinagawa K, Ishimaru F, Niiya K, Miura I, Tanimoto M, Harada M. Multilineage involvement in hypereosinophilic syndrome terminating in granulocytic sarcoma and leukaemic transformation with trisomy 8. *Br J Haematol.* 2002; 119:716-719.
22. Takata S, Kojima K*, Fujii N, Kaneda K, Yoshida C, Hashimoto D, Asakura S, Shinagawa K, Tanimoto M. Successful treatment with cyclosporin A for myelodysplastic syndrome with erythroid hypoplasia associated with t(6;8)(q15;q22). *Cancer Genet Cytogenet.* 2003; 140:167-169. (Renamed as Cancer Genetics)
23. Kojima K*, Fujii N, Omoto E, Nose S, Yoneyama M, Sugii Y, Hiramatsu H, Chikatsune M, Sato M, Takata S, Itoshima T, Tanimoto M. Cyclic thrombocytopenia and polycythemia vera. *Ann Hematol.* 2003; 82:61-63.
24. Kozuka T, Kojima K*, Kaneda K, Takenaka K, Manabe Y, Hirata Y, Okuma S, Toki H, Tanimoto M. Autoimmune neutropenia associated with multiple sclerosis. *Intern Med.* 2003; 42:102-104.
25. Kojima K*, Imaoka M, Noguchi T, Narumi H, Uchida N, Sakai I, Yasukawa M, Fujita S. Hypocellular acute promyelocytic leukemia with a tetraploid clone characterized by two 15;17 translocations. *Cancer Genet Cytogenet.* 2003; 145:169-171. (Renamed as Cancer Genetics)

26. Narumi H, Kojima K*, Matsuo Y, Shikata H, Sekiya K, Niiya T, Bando S, Niiya H, Azuma T, Yakushijin Y, Sakai I, Yasukawa M, Fujita S. T-cell large granular lymphocyte leukemia occurring after autologous peripheral blood stem cell transplantation. *Bone Marrow Transplant.* 2004;33:99-101.
27. Azuma T*, Narumi H, Kojima K, Nawa Y, Hara M. Hyponatremia during administration of tacrolimus in an allogeneic bone marrow transplant recipient. *Int J Hematol.* 2003; 78:268-269.
28. Fujimoto TT*, Kishimoto M, Ide K, Mizushima M, Mita M, Sezaki N, Kojima K, Shinagawa K, Niiya K, Tanimoto M, Fujimura K. Glanzmann thrombasthenia with acute myeloid leukemia successfully treated by bone marrow transplantation. *Int J Hematol.* 2005; 81:77-80.
29. Yakushijin Y*, Shikata H, Kito K, Ohshima K, Kojima K, Hato T, Hasegawa H, Yasukawa M. Follicular dendritic cell tumor as an unknown primary tumor. *Int J Clin Oncol.* 2007; 12:56-58.
30. Ravella PM, Liu D, Kojima K, Weisberger J, Miura O, Kuyama J, Au W, Seiter K*. Acute promyelocytic leukemia with tetraploid karyotype. First report in the Western hemisphere and update of previous reports. *Leuk Res.* 2011; 35:e93-e95.
31. Kitamura H*, Ando T, Kojima K, Komiya K, Sueoka-Aragane N, Kimura S. Diffuse bone marrow uptake of fluorodeoxyglucose in a patient with aleukaemic acute lymphoblastic leukaemia. *Br J Haematol.* 2014; 166:2.
32. Kamachi K, Kojima K*, Nishijima A, Takeshita M, Ando T, Kimura S. Small lymphocytic lymphoma presenting as bulky renal incidentaloma. *Int J Hematol.* 2014; 100:107-108.
33. Kamachi K, Fukushima N*, Ando T, Sato K, Ohshima K, Yokoo M, Shindo T, Kubota Y, Kojima K, Kimura S. Coexistence of ALK-anaplastic large cell lymphoma and CD4+ T cell large granular lymphocytic leukemia. *Ann Hematol.* 2015; 94:539-540.
34. Yoshimura M, Kojima K*, Tomimasu R, Fukushima N, Hayashi S, Sueoka E, Kimura S. ABL tyrosine kinase inhibitor-induced pulmonary alveolar proteinosis in chronic myeloid leukemia. *Int J Hematol.* 2014; 100:611-614.
35. Ando T, Kojima K*, Isoda H, Eguchi Y, Honda T, Ishigami M, Kimura S. Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia. *Int J Hematol.* 2015; 102:379-382.

36. Ureshino H*, Ando T, Kojima K, Itamura H, Jinnai S, Doi K, Ohshima K, Kurogi K, Miyahara M, Kimura S. Rituximab-containing Chemotherapy (R-CHOP)-induced Kaposi's Sarcoma in an HIV-negative Patient with Diffuse Large B Cell Lymphoma. *Intern Med.* 2015; 54:3205-3208.
37. Ureshino H, Nishioka A, Kojima K*, Suzuki M, Kizuka H, Sano H, Shindo T, Kubota Y, Ando T, Kimura S. Rituximab-induced Acute Thrombocytopenia in High Tumor Burden Follicular Lymphoma. *Intern Med.* 2016; 55:2061-2064.
38. Ureshino H, Nishioka A, Kojima K*, Kizuka H, Sano H, Shindo T, Kubota Y, Ando T, Kimura S. Subdural Hematoma Associated with Dasatinib and Intrathecal Methotrexate Treatment in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia. *Intern Med.* 2016; 55:2703-2706.
39. Kusaba K, Kojima K*, Naito S, Taba M, Kai K, Ureshino H, Nishida Y, Kimura S. Paraneoplastic Sarcoidosis in Multiple Myeloma. *Intern Med.* 2017; 56:2049-2051.
40. Ureshino H*, Kizuka H, Kusaba K, Sano H, Nishioka A, Shindo T, Kubota, Y, Ando T, Kojima K, Kimura S. 5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10). *Int J Hematol.* 2017; 105:692-696.
41. Ureshino H*, Ando T, Kizuka H, Kusaba K, Sano H, Nishioka A, Itamura H, Shindo T, Kubota Y, Kojima K, Kimura S. Tocilizumab for severe cytokine-release syndrome after haploidentical donor transplantation in a patient with refractory Epstein-Barr virus-positive diffuse large B-cell lymphoma. *Hematol Oncol.* 2018;36:324-327.
42. Kitamura H, Kubota Y*, Yamaguchi K, Kamachi K, Nishioka A, Yokoo M, Shindo T, Ando T, Kojima K, Kimura S. Successful Autologous Hematopoietic Stem Cell Transplantation Followed by Bortezomib Maintenance in a Patient with Relapsed CD138-low Multiple Solitary Plasmacytomas Harboring a 17p Deletion. *Intern Med.* 2018;15;57:855-860.
43. Nishioka A, Ureshino H*, Ando T, Kizuka H, Kusaba K, Sano H, Itamura H, Kubota Y, Kojima K, Ohshima K, Kimura S. Three coexisting lymphomas in a single patient: composite lymphoma derived from a common germinal center B-cell precursor and unrelated discordant lymphoma. *Int J Hematol.* 2018;107:703-708.
44. Ando T, Kojima K*, Sano H, Kidoguchi K, Kusaba K, Yoshimura M, Yokoo M, Kubota Y, Nakamura H, Takase Y, Aishima S, Kimura S. Successful treatment of post-transplant

relapsed adult T cell leukemia after cord blood transplantation with low-dose, short-term lenalidomide. *Leuk Lymphoma*. 2018;59:2474-2477.

45. Kidoguchi K, Yoshimura M, Kojima K*, Ureshino H, Egashira R, Yokoo M, Kai K, Egashira Y, Ohshima K, Ando T, Kimura S. Oral ulceration: an unusual manifestation of lymphomatoid granulomatosis. *Ann Hematol*. 2019;98:1305-1307.
46. Yokoo M, Kojima K*, Sano H, Kai K, Arakawa F, Ohshima K, Matsunaga T, Kimura S. Locally distributed multicentric plasmacytomas in the ileum secondary to lymphoma chemoimmunotherapy. *Ann Hematol*. 2019;98:1501-1503.
47. Kidoguchi K, Kojima K*, Seki R, Nagafuji K, Ohshima K, Kimura S. Is clinicopathological distinction of mucosa-associated lymphoid tissue lymphoma from Waldenström macroglobulinemia essential in MYD88 L265P mutation-positive cases? *Int J Hematol*. 2019;109:247-248.
48. Kamachi K, Kubota Y*, Nagaie T, Yamaguchi Y, Ogusu S, Kidoguchi K, Kusaba K, Kizuka-Sano H, Nishioka A, Yoshimura M, Yokoo M, Ando T, Kai K, Kojima K, Ohshima K, Sueoka E, Kimura S. Primary chest wall MYC/BCL6 double-hit lymphoma with t(3;7)(q27;p12) and t(8;14)(q24;q32) translocations. *Intern Med*. 2019; 58:2073-2077.
49. Kidoguchi K, Kojima K*, Yokoo M, Kimura S. BCR-ABL1- and CBFβ-MYH11-positive chronic myeloid leukemia presenting with primary blast crisis and marrow fibrosis. *Ann Hematol*. 2019;98:2461-2462.
50. Kidoguchi K, Kubota Y, Kusaba K, Kizuka-Sano H, Yamaguchi K, Nishioka A, Yokoo M, Ando T, Kojima K, Kimura S. Severe infusion reaction, anti-rituximab antibodies and lymphoma. *QJM*. 2020;113:273-274.
51. Ogasawara F, Nakatani Y, Kojima K*. Superior vena cava lymphoma. *Intern Med*. 2020;59:1231.
52. Fujita M, Kamachi K*, Yokoo M, Kidoguchi K, Kusaba K, Kizuka-Sano H, Yamaguchi K, Nishioka A, Yoshimura M, Kubota Y, Ando T, Kojima K, Kimura S. Accelerated Phase of Atypical Chronic Myeloid Leukemia with Severe Disseminated Intravascular Coagulation at Initial Presentation. *Intern Med*. 2020;59:1549-1553.
53. Ando T, Sano H, Yokoo M, Kusaba K, Kidoguchi K, Yamaguchi K, Katsuya H, Yoshihara S, Kubota Y, Kojima K, Kimura S. Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor. *Int J Hematol*. 2020;112:249-253.

54. Nakamura M, Saeki K, Egashira R, Egashira Y, Kojima K*. Gastric emphysema in chemosensitive gastric diffuse large B cell lymphoma. *Ann Hematol.* 2020;99:2457-2458.
55. Kamachi K, Ando T, Tsuruoka N, Hashiguchi M, Kidoguchi K, Kusaba K, Sano H, Yamaguchi K, Nishioka A, Yoshimura M, Yokoo M, Kubota Y, Kojima K, Kimura S. Successful Anti-TNF-alpha Therapy for Crohn's Disease After Allogeneic Stem Cell Transplantation. *Tohoku J Exp Med.* 2020;251:81-85.
56. Ureshino H, Shindo T*, Sano H, Kubota Y, Ando T, Kidoguchi K, Kusaba K, Itamura H, Kojima H, Kusunoki Y, Miyazaki Y, Kojima K, Tanaka H, Saji H, Oshima K, Kimura S. Reconstitution of NK cells expressing KIR3DL1 is associated with reduced NK cell activity and relapse of CML after allogeneic hematopoietic stem cell transplantation. *Int J Hematol.* 2020;111:733-738.
57. Saeki K, Nakamura M, Kojima K*. Primary pulmonary diffuse large B-cell lymphoma presenting as bulky bilateral lung tumors. *Ann Hematol.* 2021;100:577-578.
58. Nakamura M, Iwasa H, Kojima K*. Central nervous system involvement in mantle cell lymphoma presenting magnetic resonance imaging features of mild encephalitis/encephalopathy with a reversible splenic lesion. *Intern Med.* 2021;60:1597-1600
59. Togitani K*, Iguchi M, Asagiri T, Ogasawara F, Murakami I, Kojima K. Glucocorticoid-induced redistribution lymphocytosis in mantle cell lymphoma with hyaline vascular Castleman disease-like features. *J Clin Exp Hematop.* 2022;62:46-51.
60. Togitani K*, Asagiri T, Iguchi M, Igawa T, Yoshino T, Kojima K. Systemic Abscopal Effect of Low-dose Radiotherapy (2 Gy ×2) against Palatine Tonsil Follicular Lymphoma. *Intern Med.* 2022;61:3107-3110.
61. Kadowaki Y, Nishiyama M*, Nakamura M, Morisaka H, Fujimoto S, Terada Y, Kojima K. Adult-onset Langerhans cell histiocytosis changing CNS lesion from pituitary to suprasellar extension. *Endocrinol Diabetes Metab.* 2022;2022;22-0232.
62. Togitani K*, Ogasawara F, Arakawa Y, Sugimura N, Miyazaki R, Kojima K. Psoas and mediastinal abscesses during intravenous tocilizumab treatment in multicentric Castleman disease. *Intern Med.* 2023;62:449-452.
63. Kondo T, Iguchi M, Yoshida S, Yoshino T, Kojima K*. Cyclin D2-positive mantle cell lymphoma with t(2;12)(p12;p13) arising in immune deficiency/dysregulation. *Ann Hematol* 2023;102:2639-2640.

64. Eda H, Arakawa Y, Yoshida T, Ogasawara F, Kojima K, Nakaminami H, Yamagishi Y*. Unilateral lymphadenitis caused by community-associated methicillin-resistant *Staphylococcus aureus* ST834 strain. *J Infect Chemother*. 2023;S1341-321X(23)00309-4.
65. Tsuge N, Ogasawara F, Kondo T, Yoshida S, Kojima K*. A novel four-way translocation variant t(8;14;15;21)(q22;q22;q15;q22.1) in acute myeloid leukemia with *RUNX1::RUNX1T1*. *Turk J Haematol* 2024;41:128-129.
66. Kondo T, Ohara K, Yoshida S, Kojima K*. Development of disseminated intravascular coagulation in asymptomatic leukemic non-nodal mantle cell lymphoma. *Ann Hematol*. 2024;103:3273-3275.

英文総説/Review Papers (*: corresponding author)

1. Kojima K*, Hara M, Sawada T, Miyata A, Saito H, Matsuo Y, Yasukawa M, Fujita S, Harada M. Human T-lymphotropic virus type I provirus and T-cell prolymphocytic leukemia. *Leuk Lymphoma*. 2000; 38: 381-386.
2. Kimura S*, Ando T, Kojima K. Ever-advancing chronic myeloid leukemia treatment. *Int J Clin Oncol*. 2014; 19:3-9.
3. Ishizawa J, Kojima K, Hail N Jr, Tabe Y, Andreeff M. Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein. *Pharmacol Ther*. 2015; 153:25-35.
4. Kojima K*, Ishizawa J, Andreeff M. Pharmacological activation of wild-type p53 in the therapy of leukemia. *Exp Hematol*. 2016; 44:791-798.
5. Kojima K*, Burger JA. Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies. *J Clin Exp Hematop*. 2020; 60:130-137.

英文著書/Book Chapters (*: corresponding author)

1. Kojima K*, Vassilev LT. Targeting p53 tumor suppressor for AML therapy. In “Targeted Therapy of Acute Myeloid Leukemia”, ed. Michael A., pp.135-150, Springer, Berlin, 2015.
2. Kojima K*, Andreeff M. TP53. In “Targeted Therapy in Translational Cancer Research”, ed. Tsimberidou AM, Kurzrock R, Anderson KC., pp. 353-359, John Wiley & Sons, Hoboken, NJ, 2015.

邦文 (原著・症例報告・総説・著書)

原著

1. 小島研介. 骨髓異形成症候群における Sideroblastogram の臨床的意義に関する検討. 岡山医学会雑誌, 1994;106:893-906.
2. 名和由一郎, 野口寿行, 小島研介, 原雅道. 非寛解期多発性骨髓腫における同種骨髓移植: graft-versus-myeloma 効果の存在. 臨床血液, 2001;42:481-487.

症例報告

1. 森 公介, 小島研介, 安藤陽夫, 清水信義. 術前化学療法, 放射線療法が著効した胸腺未分化癌の 1 例. 肺癌, 1995;35:357-62.
2. 竹内誠, 小島研介, 高場成治, 磯川正史, 谷水将邦, 木村文昭, 大本英次郎, 原田実根. Cytarabine Ocfosfate 長期投与にて良好な経過を得た骨髓異形成症候群の 1 例. 癌と化学療法, 1995;22:141-144.
3. 小島研介, 森公介, 亀井治人, 上岡博, 大熨泰亮, 原田実根. 多発性の肺内転移巣に薄壁空洞を生じた中分化型肺腺癌の一例. 日胸疾会誌, 1996;34:96-100.
4. 小島研介, 井上祐子, 福田俊一, 瀬崎達雄. 高カルシウム血症と parathyroid-hormone related-peptide および IL-6 の上昇を認めた B 細胞性急性リンパ性白血病の一例. 骨転移 1997;13:9-12.
5. 原雅道, 小島研介, 東太地, 成見弘, 品川克至. High-risk MDS (RAEB, RAEBt) に対する cytarabine ocfosfate, 少量 etoposide, G-CSF 併用療法の試み. 臨床血液, 1998;39:314-316.
6. 東太地, 原雅道, 小島研介, 名和由一郎. ドナーリンパ球輸注後に認められた急速な造血回復と “periangraftment syndrome” 様症状. 臨床血液, 1999;40:59-62.
7. 原雅道, 東太地, 名和由一郎, 小島研介, 澤田妙子, 上岡樹生, 田口博國, 三好勇夫. 同種骨髓移植を施行した成人 T 細胞性白血病 (ATL) の一例. 日本内科学会雑誌, 1999;88:334-335.
8. 小島研介, 新居一郎, 杉山満美, 佐々木健二, 原雅道. リウマチ性多発筋痛症を合併した骨髓異形成症候群. 臨床血液, 2000;41:222-224.

9. 原雅道, 成見弘, 名和由一郎, 小島研介, 重松 武. 宗教上の理由により輸血を拒否した急性骨髄性白血病の一例. 日本臨床内科医会誌, 2001;16:203-205.
10. 宮田明, 吉野正, 小島研介, 藤井総一郎, 菊池武志. 胃の diffuse large B-cell lymphoma を合併した T-cell prolymphocytic leukemia. 臨床血液, 2001;42:47-50.
11. 金田衣代, 小島研介, 品川克至, 石丸文彦, 池田和真, 新谷憲治, 原田実根. 急性血小板減少が先行した成人水痘. 臨床血液, 2001;42:1142-1144.
12. 中西徳彦, 小島研介, 上田暢男, 森高智典. 骨髄移植後に発症した Bronchiolitis obliterans と思われる呼吸器障害の診断に吸気呼気 CT が有用であった 1 例. 日呼吸会誌, 2002;40:408-411.
13. 松原悦子, 酒井郁也, 成見弘, 木村行雄, 小島研介, 東太地, 内田直之, 薬師神芳洋, 安川正貴, 藤田繁, 羽藤高明. 急性骨髄性白血病発症直前に出現し白血病の病勢とともに消退と増悪を繰り返した皮膚サルコイド反応. 日本内科学会雑誌, 2005;94:2192-2194.
14. 小笠原史也, 伊藤孟彦, 中村真, 佐伯恭昌, 谷口重裕子, 砥谷和人, 小島研介. ステロイド治療中に後天性フィブリノゲン低下症をきたした白血病. 臨床血液, 2021;62:193-195.
15. 砥谷和人, 朝霧正, 上岡樹生, 小島研介. バリエント e13a3 (b2a3) BCR-ABL1 慢性骨髄性白血病の良好な ABL1 チロシンキナーゼ阻害剤感受性. 臨床血液, 2021;62:180-185.
16. 砥谷和人, 江田雅志, 朝霧正, 小島研介. 国内未承認の輸入サプリメントによる鉛中毒. 臨床血液, 2021;62:267-269.
17. 宮崎詩織, 西田愛恵, 朝霧正, 重留一貴, 木田和伸, 久川浩章, 砥谷和人, 小島研介. APTT 試薬による偽性 APTT 延長症. 臨床血液, 2021;62:1515-1518.
18. 江田仁海, 渡部伸一郎, 小笠原史也, 佐伯恭昌, 吉田将平, 砥谷和人, 武内あかり, 宮崎詩織, 小島研介. 健康診断で好中球減少を指摘された無症候性の早期急性前骨髄球性白血病～末梢血 WT1 mRNA 測定の有用性. 臨床血液, 2022;63:1520-1524.
19. 大原慶斗, 津下典子, 渡部伸一郎, 江田仁海, 小笠原史也, 近藤匠, 吉田将平, 小島研介. Ferroportin disease における妊娠・出産時の鉄代謝管理. 臨床血液, 2023;64:1410-1414.
20. 渡部伸一郎, 中路康介, 越智経浩, 和田倫子, 小笠原史也, 吉田将平, 小島研介. 原発性胆汁性胆管炎に合併した肝原発びまん性大細胞型 B 細胞リンパ腫. 臨床血液 2024;65:1480-1484.

総説

1. 小島研介. p53 と白血病. 臨床血液, 2014;55:1724-1730.
2. 小島研介. イブルチニブ. 日本病院薬剤師会雑誌, 2016;52:1521-1525.
3. 小島研介. 分子標的治療時代の慢性リンパ性白血病治療戦略. 臨床血液, 2020;61:1275-1280.
4. 小島研介. TP53 変異骨髄異形成症候群/急性骨髄性白血病 (MDS/AML)の病態と臨床. 臨床血液, 2023;64:955-961.
5. 小島研介. 急性骨髄性白血病の診断と治療のいま. 日本検査血液学会雑誌 (印刷中)

著書

1. 小島研介. 急性リンパ性白血病患者へのインフォームド・コンセントの進め方, インフォームド・コンセント ガイダンス-血液疾患診療編, 月本一郎編, pp. 236-244, 先端医学社, 東京, 2001.
2. 小島研介, 原田実根. 血液疾患とステロイド療法, PTM (Physicians' Therapy Manual) 『最新の疾患別治療マニュアル』 (11), pp. 1-2, 日本メディス株式会社, 東京, 2001.
3. 小島研介. Mdm2 アンタゴニストによる白血病細胞のアポトーシス, 急性前骨髄球性白血病 (APL), 血液・腫瘍科 (53), pp. 71-75, 科学評論社, 東京, 2006.
4. 小島研介. CLL における fludarabine 耐性機構とその克服, 慢性リンパ性白血病 (CLL), 血液・腫瘍科 (55), pp. 83-86, 科学評論社, 東京, 2007.
5. 小島研介. 変異FLT3急性骨髄性白血病に対する治療戦略としてのFLT3阻害と p53 活性化, 細胞死と造血器腫瘍, 血液内科 (62), pp. 220-225, 科学評論社, 東京, 2011.
6. 小島研介, 安藤寿彦, 木村晋也. リンパ性白血病における分子標的治療, 血液疾患の分子標的薬, 日本臨牀 (72), pp. 1094-1098, 日本臨牀社, 東京, 2014.
7. 田部陽子, 小島研介. 造血器腫瘍における p53-HDM2 系異常, 血液疾患の分子標的薬, 日本臨牀 (72), pp. 1042-1046, 日本臨牀社, 東京, 2014.
8. 小島研介, 木村晋也. 慢性骨髄性白血病の病態と治療, 白血病の成因と治療, BIO Clinica, pp. 33-38, 北隆館, 東京, 2014.

9. 小島研介, 末岡榮三朗. 白血球増多・減少, 日常診療のための検査値のみかた, 野村文夫, 村上正巳, 和田隆志, 末岡榮三朗編, pp. 7-12, 中外医学社, 東京, 2015.
10. 小島研介. ゲムツズマブオゾガマイシン, 新 ABC 血液領域の分子標的治療薬, 畠清彦編, pp. 21-26, 最新医学社, 大阪, 2015.
11. 小島研介, 木村晋也. 治療総論・分子標的治療薬, Principles and Practice 血液・造血器・リンパ系, 千葉滋編, pp. 136-141, 文光堂, 東京, 2015.
12. 小島研介, 木村晋也. T315I 変異に対する治療, 白血病・リンパ腫薬物療法ハンドブック, 松村 到編, pp. 162-167, 南江堂, 東京, 2016.
13. 小島研介, 木村晋也. 変異遺伝子の同定と定量, Ph 陰性骨髄増殖性腫瘍～分子病態と治療の最前線～, 金倉讓編, pp. 34-44, 医薬ジャーナル社, 大阪, 2016.
14. 小島研介, 木村晋也. 最新の基礎研究動向：概論, 多発性骨髄腫学, 谷脇雅史編, pp. 139-143, 日本臨牀社, 東京, 2016.
15. 小島研介. 白血病：急性白血病の診断と治療, がんの先進医療, 基佐江里編, pp. 14-17, 露書房, 神奈川, 2016.
16. 小島研介, 木村晋也. ABL/KIT/PDGFR 阻害薬, がん分子標的薬の効果と副作用, 日本臨牀 (75), pp. 1388-1392, 日本臨牀社, 東京, 2016.
17. 小島研介. 治療のプロトコール：慢性リンパ性白血病 (CLL), 白血病治療マニュアル (改訂第4版), 清井仁・宮本敏浩編, pp. 161-168, 南江堂, 東京, 2020.
18. 小島研介. :II. 造血器腫瘍の基礎：細胞周期 (TP53 含む), 日本臨牀増刊号 造血器腫瘍学 (第2版), 柴山浩彦・金倉讓編, pp. 73-78, 日本臨牀社, 東京, 2020.
19. 砥谷和人, 小島研介. 慢性リンパ性白血病に対する分子標的治療の進展, 血液内科 (81), pp. 455-461, 科学評論社, 東京, 2020.
20. 小島研介. 現在の標準治療：CLL/SLL に対する治療戦略, リンパ腫の診療 update, 日本臨牀 (79), pp. 359-364, 日本臨牀社, 東京, 2021.
21. 佐伯恭昌, 小島研介. 慢性リンパ性白血病, 特集：大きく進歩した造血器腫瘍の診断と治療, 診断と治療 (109), pp. 787-790, 診断と治療社, 東京, 2021.

22. 小島研介. 高知県の血液内科学 病理と処方箋. 高知県医師会医学雑誌第 26 巻 1 号, pp. 264-269, 高知県医師会, 2021.
23. 小島研介. 質疑応答 プロからプロへ：慢性リンパ性白血病の初回治療で免疫化学療法と BTK 阻害剤の使い分けのポイント, 日本医事新報 (5065), pp. 47-48, 日本医事新報社, 2021.
24. 小島研介. 慢性リンパ性白血病における BTK 阻害薬と BCL2 阻害薬選択の考え方と注意点, 造血器腫瘍における新規薬剤選択の考え方と注意点, 血液内科 (82), pp. 790-795, 科学評論社, 東京, 2021.
25. 小島研介. 質疑応答・プロからプロへ：同種移植後を含めた、急性骨髄性白血病に対する FLT3 阻害薬の使い方 (Q) . 日本医事新報 (5068), p. 49, 日本医事新報社, 東京, 2021.
26. 小島研介. 慢性リンパ性白血病における BCL2 阻害薬の耐性機序, 造血器腫瘍に対する分子標的薬の耐性機序, 血液内科 (83), pp. 473-478, 科学評論社, 東京, 2021.
27. 小島研介. 慢性リンパ性白血病の薬剤耐性とその克服, 慢性白血病 –最新の診断と治療–, 日本臨牀 (79), pp.1782-1787, 日本臨牀社, 東京, 2021.
28. 小島研介. 慢性リンパ性白血病に対する新規分子標的治療, 造血器腫瘍に対する新規治療薬, 腫瘍内科 (29) , pp. 427-431, 科学評論社, 東京, 2021.
29. 小島研介. 慢性リンパ性白血病, 今日の治療指針 私はこう治療している 2022 年版, pp. 695-697, 医学書院, 東京, 2022.
30. 小島研介. 慢性リンパ性白血病, 生涯教育シリーズ-102 血液疾患のすべて, 日本医師会雑誌(151), pp.256-257, 日本医師会, 東京, 2022.
31. 小島研介. 慢性リンパ性白血病のリスク評価と治療選択, 層別化される悪性リンパ腫の病態と診療, 血液内科 (84) , pp. 333-338, 科学評論社, 東京, 2022.
32. 小島研介. 初発 CLL の治療方針, EBM 血液疾患の治療 2023-2024, pp.238-242, 中外医学社, 東京, 2022.
33. 小島研介. CLL セカンドライン治療における BTK 阻害薬と BCL2 阻害薬の使い分け, 造血器腫瘍の治療開発における unanswered questions - エビデンスと今後の展望, 血液内科 (85) , pp. 510-514, 科学評論社, 東京, 2022.
34. 小島研介, 高松泰. 慢性リンパ性白血病, 日本血液学会造血器腫瘍診療ガイドライン 2023, pp. 147-172, 金原出版, 東京, 2023.

35. 小島研介. 慢性リンパ性白血病の molecular map, 特集 造血器腫瘍における微小残存病変 (MRD) の評価と臨床的意義, 血液内科 (86) , pp, 889-894, 科学評論社, 東京, 2023.
36. 小島研介. 慢性リンパ性白血病, 今日の診断指針 第9版, pp. X-X, 医学書院, 東京, 2024.
37. 小島研介. 慢性リンパ性白血病における微小残存病変による治療調整, 特集/造血器疾患における動物モデルを用いた病態解明, 血液内科 (89) , pp, 63-67, 科学評論社, 東京, 2024.
38. 小島研介. CLLに対する今後の分子標的治療薬, EBM 血液疾患の治療 2025-2026, pp. 266-270, 中外医学社, 東京, 2024.
39. 小島研介. 【Chapter 3: ここまで来た！白血病の治療】慢性リンパ性白血病, 広く浅く知る白血病, 臨床雑誌「内科」, pp. 898-901, 南江堂, 東京, 2024.